<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.28932.004</object-id><label>Table 1.</label><caption><title>Demographics of patients in the model study populations.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">ERASMOS <break/>(n&#160;=&#160;60)</th><th valign="top">PMP/NECC (n&#160;=&#160;119*)</th><th valign="top">p-value</th></tr></thead><tbody><tr><td valign="top">Age, years, median (SD)<sup>&#8224;</sup></td><td valign="top">57 (9.8)</td><td valign="top">56 (7.1)</td><td valign="top">0.44</td></tr><tr><td valign="top">CA-125, units/ml, median (SD) <sup>&#8224;</sup></td><td valign="top">155 (689.8)</td><td valign="top">88.1 (1335.5)</td><td valign="top">0.72</td></tr><tr><td valign="top">Histology, n (%)<sup>&#8225;</sup></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;Control</td><td valign="top">0 (0)</td><td valign="top">15 (12.6)</td><td valign="top">&lt;0.0001</td></tr><tr><td valign="top">&#8195;Serous cystadenoma/cystadenofibroma</td><td valign="top">7 (11.7)</td><td valign="top">14 (11.8)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Endometrioma</td><td valign="top">0 (0)</td><td valign="top">15 (12.6)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Other benign lesion</td><td valign="top">9 (15.0)</td><td valign="top">0 (0)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Borderline mucinous tumor</td><td valign="top">2 (3.3)</td><td valign="top">0 (0)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Borderline serous tumor</td><td valign="top">5 (8.3)</td><td valign="top">15 (12.6)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Stage I/II serous adenocarcinoma</td><td valign="top">5 (8.3)</td><td valign="top">20 (16.8)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Stage III/IV serous adenocarcinoma</td><td valign="top">19 (31.2)</td><td valign="top">10 (8.4)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Stage I/II clear cell/endometrioid adenocarcinoma</td><td valign="top">6 (10.0)</td><td valign="top">20 (16.8)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Stage III/IV clear cell/endometrioid adenocarcinoma</td><td valign="top">0 (0)</td><td valign="top">10 (8.4)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Mucinous adenocarcinoma</td><td valign="top">1 (1.7)</td><td valign="top">0 (0)</td><td valign="top"/></tr><tr><td valign="top">&#8195;Other ovarian cancer</td><td valign="top">10 (10.0)</td><td valign="top">0 (0)</td><td valign="top"/></tr><tr><td valign="top">Stage, n (%)<sup>&#8225;</sup></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Not applicable</td><td valign="top">16 (26.7)</td><td valign="top">59 (49.6)</td><td valign="top">&lt;0.0001</td></tr><tr><td valign="top">&#8195;I</td><td valign="top">9 (15.0)</td><td valign="top">22 (18.5)</td><td valign="top"/></tr><tr><td valign="top">&#8195;II</td><td valign="top">8 (13.3)</td><td valign="top">18 (15.1)</td><td valign="top"/></tr><tr><td valign="top">&#8195;III</td><td valign="top">19 (31.2)</td><td valign="top">18 (15.1)</td><td valign="top"/></tr><tr><td valign="top">&#8195;IV</td><td valign="top">8 (13.3)</td><td valign="top">2 (1.7)</td><td valign="top"/></tr><tr><td valign="top">Grade, n (%)<sup>&#8225;</sup></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;Not applicable</td><td valign="top">16 (26.7)</td><td valign="top">44 (37.0)</td><td valign="top">0.07</td></tr><tr><td valign="top">&#8195;Borderline</td><td valign="top">7 (11.7)</td><td valign="top">15 (12.6)</td><td valign="top"/></tr><tr><td valign="top">&#8195;1 (well-differentiated)</td><td valign="top">6 (10.0)</td><td valign="top">12 (10.1)</td><td valign="top"/></tr><tr><td valign="top">&#8195;2 (moderately differentiated)</td><td valign="top">3 (5.0)</td><td valign="top">12 (10.1)</td><td valign="top"/></tr><tr><td valign="top">&#8195;3 (poorly differentiated)</td><td valign="top">28 (46.7)</td><td valign="top">36 (30.3)</td><td valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>ERASMOS &#8211; Effects of Regional Analgesia on Serum miRNA after Oncology Surgery Study</p><p>PMP &#8211; Pelvic Mass Protocol</p></fn><fn><p>NECC &#8211; New England Case Control study</p><p>*15samples from NECC, 114 samples from PMP</p></fn><fn><p><sup>&#8224;</sup>student&#8217;s t-test</p><p><sup>&#8225;</sup>chi-square test</p></fn></table-wrap-foot></table-wrap>